Researched and fact-checked in-house against primary literature and regulator records. Not reviewed by a named clinician — how we work.
Evidence-rated reference Updated August 2026
We sell nothing. No vendor sponsorship. Editorial policy
pepteyes .com

GLP-1 & Metabolic

The GLP-1 Plateau: What the Trial Curves Actually Show

Semaglutide and tirzepatide weight curves flatten months before the trials end. That flattening is energy balance settling at a new equilibrium, not the drug wearing off.

Why the weight curve flattens before the trial ends

In every large obesity trial of these drugs the mean weight curve does the same thing. It falls steeply for the first six months or so, bends through the second half of the first year, and then approaches something close to horizontal. That flattening is the point at which the reduction in energy intake the drug produces is offset by the reduction in energy the smaller body needs. Nothing about the drug has changed. The equation on the other side of it has.

This distinction matters because a plateau is routinely read as the drug having stopped working, and the two situations look identical on a bathroom scale. They do not look identical in a trial. When treatment is withdrawn at plateau, weight climbs back promptly. A drug that had genuinely stopped working could be removed without consequence, and that is not what the withdrawal trials found.

Where the plateau lands differs by drug and by population. Semaglutide 2.4 mg weekly settles near a mean of fifteen percent below baseline in the pivotal obesity trials. Tirzepatide at its highest studied dose settles nearer twenty percent. In SELECT, run in an older population with established cardiovascular disease and no diabetes, the mean loss plateaued closer to ten percent by around week 65 and stayed there for the rest of a four-year trial.

What the published curves actually show

STEP 1 randomised 1,961 adults with obesity, or overweight plus a weight-related condition and without diabetes, to semaglutide 2.4 mg weekly or placebo for 68 weeks alongside lifestyle intervention. Mean change was about 14.9 percent versus 2.4 percent on placebo. The instructive part is the shape, not the headline: the descent is steepest between roughly week 8 and week 40, and the line is visibly bending by week 52 with four months of trial still to run.

STEP 5 carried the same dose out to 104 weeks and reported a mean of roughly fifteen percent, barely different from the 68-week figure in STEP 1. The second year adds very little. That is the cleanest published picture of a plateau being held rather than lost, and it is the single most useful curve for anyone trying to understand what a year of flat weight on treatment means.

SURMOUNT-1 tested tirzepatide at 5, 10 and 15 mg weekly over 72 weeks in adults with obesity and without diabetes, with mean losses of roughly 15, 19.5 and 21 percent against about 3 percent on placebo. The curves are steeper and deeper than semaglutide's, and at week 72 the highest-dose curve had not fully flattened. Tirzepatide plateaus later, which is not the same as not plateauing.

SURMOUNT-4 answers the question directly. Everyone took open-label tirzepatide for 36 weeks, reaching a mean of about 21 percent, and was then randomised either to continue or to switch to placebo for a further 52 weeks. Continuers lost roughly another five percent over that year. Switchers regained around fourteen percent. Past the knee of the curve, continued treatment buys slow additional loss and, mostly, defence of what has already gone.

The energy gap closes: plateau as arithmetic

These drugs work almost entirely on the intake side. GLP-1 receptor agonism slows gastric emptying, acts on hypothalamic and hindbrain circuits that govern satiety, and reduces the intrusive preoccupation with food that patients describe. Tirzepatide adds GIP receptor agonism on top. What none of them do is raise energy expenditure; if anything it falls, because expenditure is largely a function of how much body there is to maintain and move.

So consider the arithmetic. On day one the drug opens an energy gap, perhaps several hundred kilocalories a day. Weight starts falling. But every kilogram lost trims the daily requirement, at rest and in motion. The gap narrows as the very process it drives proceeds. When the requirement has fallen to meet the new intake, the gap is zero and weight stops changing. Quantitative models of human body-weight dynamics predict exactly this: an exponential approach to a new steady state, with a time constant on the order of a year.

This is why the depth of the plateau tracks the size of the sustained intake reduction rather than the duration of treatment. A stronger, better-tolerated appetite effect finds a lower equilibrium. It does not descend indefinitely. A patient at plateau on a full dose is not failing to respond; they are at the weight that their current intake and expenditure agree on.

Metabolic adaptation: the part that is more than mass

Some of the fall in expenditure is larger than lost tissue can explain. The classic controlled feeding work by Leibel, Rosenbaum and Hirsch measured total energy expenditure after a ten percent weight reduction and found it fell by more than body composition predicted, on the order of ten to fifteen percent below expectation. That residual is what the literature calls adaptive thermogenesis, and it functions as a defence of the previous weight.

It can also be durable. Six-year follow-up of the participants from a televised weight-loss competition found resting metabolic rate still running hundreds of kilocalories per day below predicted values, in people who had regained much of the weight they lost. Adaptation did not resolve when the weight came back, which is a genuinely uncomfortable finding and one of the better arguments for treating obesity as a chronic condition rather than an episode.

How much adaptive thermogenesis occurs specifically during pharmacologically induced weight loss is much less well characterised than it is for diet-induced loss. Better preservation of lean mass might blunt it, or the mechanism of the deficit might not matter to the hypothalamus at all; neither has been demonstrated convincingly. The honest summary is that the plateau is mostly arithmetic, with an adaptive component that places the equilibrium somewhat higher than mass alone would predict.

Counter-regulation: appetite pushes back

Weight loss also changes the hormonal signals that govern hunger. Leptin falls roughly in proportion to fat mass. Ghrelin rises. Subjective hunger ratings after diet-induced weight loss increase and remain elevated a year or more later, which is the physiological reason unassisted maintenance is so hard. None of this is unique to drug-treated loss; it is what happens to anyone who gets smaller.

GLP-1 receptor agonism opposes that drive but does not switch it off. Over months, a constant pharmacological suppression of appetite runs into a steadily rising counter-regulatory signal, and intake drifts back toward requirement even though the dose has not changed. Plasma concentrations of these drugs reach steady state within weeks of a stable dose, so the drift is not a matter of falling exposure. It is the other side of the balance rising to meet a fixed intervention.

That is the practical content of the body weight set point idea. The set point is not a fixed number the body returns to regardless of circumstance, but it is a real defended range, and a drug that shifts it downward shifts it to a new range rather than removing the defence.

Plateau is not tolerance, and the withdrawal trials prove it

Receptor desensitisation is a real pharmacological phenomenon and a reasonable hypothesis for a fading effect. If it drove the plateau, stopping the drug at plateau should change little, because the drug would already have ceased to contribute. The randomised withdrawal designs test that prediction, and it fails.

STEP 4 ran a 20-week open-label lead-in on semaglutide, by which point participants had lost around ten to eleven percent, then randomised them to continue or to switch to placebo for 48 more weeks. Continuers reached roughly seventeen percent below baseline. Switchers gained back about seven percentage points. SURMOUNT-4 produced the same pattern from a deeper starting point. In both cases the treatment arm was still descending slowly while the placebo arm climbed.

The off-treatment follow-up of STEP 1 makes the same point from the other end. About a year after everyone stopped, participants had regained roughly two-thirds of the weight they had lost, with cardiometabolic improvements reverting in step. Prompt regain on withdrawal is the signature of a drug that is still working hard at the moment it is removed. A plateau on treatment and a loss of drug effect are opposite findings that happen to produce the same flat line.

Why escalating past the studied maximum is not supported

The labelled maintenance dose of semaglutide for weight management is 2.4 mg once weekly. Tirzepatide for weight management is labelled up to 15 mg once weekly. Those ceilings are not arbitrary caution; they are the highest doses the pivotal trials actually evaluated for efficacy and safety over 68 to 72 weeks.

Higher semaglutide doses have been studied. The STEP UP programme evaluated a 7.2 mg weekly dose against 2.4 mg and placebo and reported greater mean weight loss, on the order of a few additional percentage points, together with more nausea, vomiting and treatment discontinuation. That result is worth stating precisely: the exposure-response curve for weight is real but flattening, while the exposure-response curve for gastrointestinal adverse events is not flattening at the same rate.

What has never been tested is the thing people actually want to do, which is escalate an individual beyond the studied maximum because their own curve went flat. No trial has randomised plateaued participants to escalation versus continuation. The reasoning against it is mechanistic as well as evidentiary: if the plateau is an energy-balance equilibrium reached at near-maximal receptor engagement, additional occupancy is a weak lever, and the adverse-event cost is not weak at all.

The compounded market makes this worse. While semaglutide and tirzepatide sat on the FDA drug shortage list, large-volume compounding was permissible; the resolution of those shortages in late 2024 and early 2025 removed that basis. Escalation schedules circulating outside the label have no efficacy evidence behind them and inherit every known dose-dependent harm, without the pharmacovigilance that a marketed product carries.

Stall or plateau: telling noise from the asymptote

The published curves are means across hundreds or thousands of people, which smooths away variation that dominates any individual record. Day-to-day body weight moves by a kilogram or two on fluid balance, glycogen stores, sodium intake, gut contents and menstrual phase. Four weeks of a flat or fractionally rising number sits comfortably inside that noise, and the trial curves take months to bend, not weeks.

Timing within treatment matters too. A flat stretch during dose titration is a different observation from a flat stretch after months at the maintenance dose, because in the first case the pharmacological intervention has not finished arriving. Titration schedules exist because tolerability, not efficacy, sets the pace of the climb to the studied dose.

Response is also genuinely heterogeneous. In STEP 1 roughly a third of participants on semaglutide reached twenty percent or more, while a minority did not reach five percent. In SURMOUNT-1 about half of the highest-dose group reached twenty percent. A mean of fifteen percent describes a wide distribution, and an individual whose plateau sits at seven percent is not necessarily a treatment failure in the way that a mean-versus-mean comparison implies.

How the plateau reframes the treatment question

If the plateau is an equilibrium rather than a malfunction, the useful question changes. It is not how to break through the flat part of the curve; it is whether the equilibrium reached is worth holding and at what cost. That is the framing behind treating obesity as a chronic disease: the medication is not a course that concludes when the curve flattens, but an ongoing input holding the balance where it is.

SELECT is the strongest evidence that the plateau is not where benefit stops. In more than 17,000 participants with overweight or obesity and established cardiovascular disease but not diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by about twenty percent in relative terms over roughly three and a half years, and the weight curve in that trial had plateaued near ten percent well before most of those events accrued. The benefit attached to being at a lower weight and a better metabolic state, not to still descending.

The evidence does not license the opposite inference either. Head-to-head data such as SURMOUNT-5, which reported greater mean weight loss with tirzepatide than semaglutide over 72 weeks, inform an initial choice between agents. They say nothing about switching agents as a response to a plateau, because nobody has run that trial. This article describes what the trials measured; it is not medical advice, and decisions about any prescribed treatment belong with the clinician who prescribed it.

What we still don't know

Every claim above has a limit. These are the questions the current evidence does not answer.

  • Whether adaptive thermogenesis after GLP-1-induced weight loss is smaller, larger or identical to that after equivalent diet-induced loss has not been settled by doubly labelled water measurement in a randomised comparison.
  • No trial has randomised people whose weight curve had flattened to dose escalation beyond the studied maximum versus continuation, so the additional loss and the adverse-event cost of that manoeuvre are both unmeasured.
  • It is unknown whether plateau depth is set mainly by achieved drug exposure, by baseline appetite biology, or by the strength of counter-regulation, and no validated predictor identifies in advance who will plateau at five percent and who at twenty-five.
  • Whether reduced-dose or intermittent maintenance after plateau defends weight as well as continued full-dose treatment has not been tested head to head against continuation.
  • How much of the plateau is attributable to lean mass lost along with fat, and whether resistance training or an add-on agent moves the asymptote rather than merely body composition, remains untested in an adequately powered trial.

Common questions

Has semaglutide stopped working if the scale has not moved for a month?
A month of flat weight is usually inside normal variation. Day-to-day weight swings by a kilogram or two on fluid, glycogen and gut contents, and the trial curves bend over months rather than weeks. More importantly, plateau and loss of drug effect are distinguishable: in STEP 4 and SURMOUNT-4, people at plateau who were switched to placebo regained substantial weight, while those who continued held or slowly extended their loss. That is the pattern of a drug still working, not one that has stopped.
Why does tirzepatide seem to keep working for longer than semaglutide?
In SURMOUNT-1 the highest-dose tirzepatide curve was still drifting downward at week 72, whereas the semaglutide curve in STEP 5 was essentially flat from around week 60. SURMOUNT-5, a head-to-head trial, reported greater mean weight loss with tirzepatide over 72 weeks. The plausible explanation is a larger and better-sustained reduction in energy intake, which finds a lower equilibrium and takes longer to reach it. It plateaus later rather than never: SURMOUNT-4 continuers added only about five percent over a further year.
Does raising the dose break through a plateau?
No trial has tested that. Higher doses have been studied as fixed assignments from the start, not as a rescue for people whose curve flattened. The STEP UP programme found a 7.2 mg weekly semaglutide dose produced a few percentage points more mean loss than 2.4 mg, with more nausea, vomiting and discontinuation. That is a flattening efficacy curve against a non-flattening adverse-event curve. Escalation beyond the labelled maximum has no efficacy evidence supporting it in a plateaued patient.
Is the plateau caused by receptors becoming desensitised to the drug?
There is no good evidence for that, and the withdrawal trials argue against it. Receptor desensitisation would predict that stopping the drug at plateau changes little, because the drug would already have stopped contributing. Instead, STEP 4, SURMOUNT-4 and the off-treatment follow-up of STEP 1 all show prompt, substantial regain when treatment is removed. Plasma concentrations also reach steady state within weeks of a stable dose, so the plateau is not a matter of falling exposure over time.
How long does it usually take to reach the plateau?
On the published mean curves, the steepest descent runs from roughly the second month to about the tenth, the curve bends noticeably through months twelve to sixteen, and by around week 60 the semaglutide curve in STEP 5 is close to horizontal and stays there through week 104. Tirzepatide at 15 mg had not fully flattened at week 72 in SURMOUNT-1. Individual timing varies widely, and titration pace shifts the whole curve, so these are the shapes of averages rather than a schedule.
If weight has stopped falling, do the health benefits stop accruing too?
The evidence points the other way. In SELECT, semaglutide 2.4 mg reduced major adverse cardiovascular events by about twenty percent in relative terms over roughly three and a half years in people with overweight or obesity and established cardiovascular disease, and the weight curve in that trial had already plateaued near ten percent before most events occurred. The benefit tracked being at a lower weight and improved metabolic state, not the rate at which weight was still falling.

What this is based on

Named sources, with what each one actually showed. We link live literature searches rather than a frozen citation list, so you can check the current record yourself.

  1. STEP 1 trial semaglutide 2.4 mg once weekly obesity 68 weeks — Randomised 1,961 adults with obesity or overweight plus a weight-related condition and without diabetes; mean weight change was about 14.9 percent with semaglutide versus 2.4 percent with placebo, with the curve already flattening before week 68. find on PubMed
  2. STEP 5 trial semaglutide 2.4 mg 104 weeks weight management — Extended treatment to two years and reported a mean loss of roughly fifteen percent, with very little additional loss after about week 60, giving the clearest published picture of a plateau being maintained rather than lost. find on PubMed
  3. STEP 4 randomised withdrawal trial semaglutide continued versus placebo — After a 20-week run-in on semaglutide, participants randomised to continue kept losing to roughly seventeen percent below baseline while those switched to placebo regained about seven percentage points. find on PubMed
  4. STEP 1 trial extension weight regain one year after withdrawal — One year after treatment and lifestyle intervention stopped, participants had regained about two-thirds of the weight lost, with cardiometabolic improvements reverting in parallel. find on PubMed
  5. SURMOUNT-1 trial tirzepatide obesity 72 weeks — Tirzepatide at 5, 10 and 15 mg weekly produced mean weight reductions of roughly 15, 19.5 and 21 percent against about 3 percent on placebo, with the highest-dose curve still descending slightly at week 72. find on PubMed
  6. SURMOUNT-4 tirzepatide randomised withdrawal after 36-week lead-in — After an open-label lead-in reaching about 21 percent loss, continuation for a further 52 weeks added roughly five percent more, whereas switching to placebo produced about fourteen percent regain. find on PubMed
  7. SURMOUNT-5 head-to-head tirzepatide versus semaglutide obesity trial — Directly compared maximum tolerated doses of the two drugs over 72 weeks and reported greater mean weight reduction with tirzepatide, informing initial agent choice rather than the management of a plateau. find on PubMed
  8. SELECT trial semaglutide cardiovascular outcomes overweight obesity — In more than 17,000 participants with established cardiovascular disease and without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by about twenty percent in relative terms while the weight curve plateaued near ten percent. find on PubMed
  9. STEP UP trial semaglutide 7.2 mg versus 2.4 mg obesity — Evaluated a higher weekly semaglutide dose and reported a modest additional mean weight reduction over 2.4 mg alongside more gastrointestinal adverse events and discontinuation. find on PubMed
  10. Leibel Rosenbaum Hirsch changes in energy expenditure resulting from altered body weight — Controlled feeding study showing that total energy expenditure after a ten percent weight reduction falls further than the change in body composition predicts, establishing adaptive thermogenesis in humans. find on PubMed
  11. Fothergill persistent metabolic adaptation six years after The Biggest Loser competition — Found resting metabolic rate still several hundred kilocalories per day below predicted six years after rapid weight loss, in participants who had regained much of the weight. find on PubMed
  12. Hall quantitative dynamic model of human body weight change — Mathematical modelling showing that a sustained change in energy intake produces an exponential approach to a new steady weight with a time constant on the order of a year, predicting the plateau shape seen in trials. find on PubMed
  13. Wegovy prescribing information semaglutide injection weight management — Establishes 2.4 mg once weekly as the labelled maintenance dose for chronic weight management, reached through a stepwise escalation schedule set by tolerability. find on PubMed
  14. Zepbound prescribing information tirzepatide injection weight management — Establishes 15 mg once weekly as the maximum labelled dose for chronic weight management, with 5 and 10 mg also approved as maintenance doses. find on PubMed

Peptides covered here

Terms used in this article

Placebo and Placebo Control
A placebo is an inactive intervention matched to the real one in appearance and route, used as a control arm so that improvement caused by the drug can be separated from improvement that would occur anyway.
Open-Label Study
An open-label study is one in which participants and investigators both know which treatment was assigned, so nothing in the design shields the results from expectation or assessment bias.
Resting Energy Expenditure (REE)
Resting energy expenditure is the energy a body uses at rest in a fasted, thermoneutral state, and it accounts for most of daily total energy expenditure.
Gastric Emptying
Gastric emptying is the rate at which stomach contents pass into the duodenum, a major determinant of postprandial glucose and of incretin therapy tolerability.
Glucose-Dependent Insulinotropic Polypeptide (GIP)
Glucose-dependent insulinotropic polypeptide is the incretin secreted by duodenal K-cells, contributing most of the incretin effect in health but blunted in type 2 diabetes.
Agonist
An agonist is a ligand that binds a receptor and stabilises its active conformation, producing a biological response rather than merely occupying the binding site.
Satiety vs Satiation
Satiation is the set of signals that ends a meal in progress, while satiety is the post-meal inhibition that determines how long it takes before eating begins again.
Glucagon-Like Peptide-1 (GLP-1)
Glucagon-like peptide-1 is an incretin hormone released by intestinal L-cells after a meal that stimulates glucose-dependent insulin secretion and suppresses appetite.
Steady State
Steady state is the condition in which the amount of drug entering the body over a dosing interval equals the amount eliminated, so concentrations repeat from interval to interval instead of climbing.
Metabolic Adaptation
Metabolic adaptation is the fall in energy expenditure after weight loss that exceeds what the smaller body size and composition alone would predict.
Lean Mass Loss
Lean mass loss is the fat-free component of weight lost during an energy deficit, encompassing muscle, organ tissue, glycogen and water rather than muscle alone.
Adiposity
Adiposity is the total quantity and anatomical distribution of body fat, treated as an active endocrine tissue rather than as inert storage.

Read next

GLP-1 & Metabolic

What Happens When You Stop a GLP-1

Stop a GLP-1 and the weight comes back. The STEP 1 extension, STEP 4 and SURMOUNT-4 measured how much returns, how fast, and what happens to blood pressure, lipids and glucose as it does.

This article is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case. We publish no dosing protocols for unapproved compounds and link to no supplier.

← All 25 articles